Member area login
You don't have or don't remember the password!
Click Here
Editor-in-chief
Maria Stella Graziani

Deputy Director
Martina Zaninotto

Associate Editors
Ferruccio Ceriotti
Davide Giavarina
Bruna Lo Sasso
Giampaolo Merlini
Martina Montagnana
Andrea Mosca
Paola Pezzati
Rossella Tomaiuolo
Matteo Vidali

EIC Assistant
Francesco Busardò

International Advisory Board Khosrow Adeli Canada
Sergio Bernardini Italy
Marcello Ciaccio Italy
Eleftherios Diamandis Canada
Philippe Gillery France
Kjell Grankvist Sweden
Hans Jacobs The Netherlands
Eric Kilpatrick UK
Magdalena Krintus Poland
Giuseppe Lippi Italy
Mario Plebani Italy
Sverre Sandberg Norway
Ana-Maria Simundic Croatia
Tommaso Trenti Italy
Cas Weykamp The Netherlands
Maria Willrich USA
Paul Yip Canada


Publisher
Biomedia srl
Via L. Temolo 4, 20126 Milano

Responsible Editor
Giuseppe Agosta

Editorial Secretary
Chiara Riva
Biomedia srl
Via L. Temolo 4, 20126 Milano
Tel. 0245498282
email: biochimica.clinica@sibioc.it

--------------------

ISSN print: 0393 – 0564
ISSN digital: 0392- 7091



BC: Articoli scritti da G. Cangemi

Indicazioni per l’armonizzazione degli intervalli terapeutici dei farmaci antibatterici
Indications for the harmonization of the therapeutic intervals of antibacterial drugs.
<p>In the last years infections due to multi-drug resistant Gram-positive and Gram-negative bacteria have increased. The accurate measurement of plasma concentrations of antibacterial drugs is crucial to identify antimicrobial therapies based on pharmacokinetics/pharmacodynamics (PK/PD) strategies. The aim of this paper is to provide an overview of the currently available information on PK/PD, minimal inhibitory concentration (MIC) and their relationships, for optimal antibacterial treatment in daily practice. Relevant papers reporting PK/PD data on different antibiotics, administered intravenously for the treatment of infections due to bacteria with reduced sensitivity or overt resistance to antibiotics, have been retrieved from the PubMed database. The classes of drugs considered were: beta-lactams, aminoglycosides, glycopeptides, lipopeptides, fluoroquinolones, tetracyclines, polymyxins and oxazolidinones. A short summary was prepared for each class of drugs and for specific drugs as well, including data on the mechanism of action, spectrum of activity and resistance, PK/PD index and target values related to MIC.&nbsp;</p>
Biochimica Clinica ; 46(4) 347
Documenti - Documents
 
Sostanze psicoattive legali, illegali, classiche e di nuova sintesi: le sfide della medicina di laboratorio
Biochimica Clinica ; 46(4) 273-275
Editoriale - Editorial
 
Titolazioni dei preparati galenici oleosi a base di cannabis in Regione Liguria: progetto sperimentale dei laboratori di riferimento regionale
Analysis of cannabinoids concentration in cannabis oil galenic preparations in the Liguria Region: experimental project of the regional reference laboratories
<p>Introduction: the medical use of cannabis is increasingly being applied in the treatment and support of several diseases and syndromes. In the Liguria Region, olive oil galenic preparations are mainly prepared by hospital pharmacies, according to common standard procedures. The preparations must be analyzed in order to establish the concentration of the two main active compounds (delta-9 tetrahydrocannabinol, THC and cannabidiol, CBD) thus allowing the correct setting of the therapeutic prescription. Liguria Region is at the forefront in the use of medical cannabis with a high number of patients treated (&gt;1000). The aim of this work is to describe the organization of the titration activity centralized at the two regional reference laboratories (Central Laboratory of Analyses of Giannina Gaslini Institute, Genova and Toxicology Laboratory of Sarzana, La Spezia), coordinated by the inter-hospital department (DIAR) of the Laboratories Area.<br />Methods: the phases of the analytical process (pre-analytical, analytical and post-analytical) have been identified and described. The analysis of the workflow has been carried out including the methods to prepare cannabis oil in the pharmacies, the intervals and production volumes, the medical-legal handling requirements and operational responsibilities. The definition of the pre-analytical phase foresees the methods of packaging, transport and recording of the samples and related responsibilities.<br />Results: the analytical phase included the development and validation of the analytical method Ultra High Performance Liquid Chromatography coupled to tandem mass spectrometry, (UHPLC-MS/MS) in the two laboratories, with common procedures and the comparison of results conducted both on reference material and real samples of olive oil galenic preparations. The definition of the post-analytical phase included the reporting procedures.<br />Discussion: the experimental phase has been concluded at the end of 2019 and the implementation phase of the project has started in march 2020.</p>
Biochimica Clinica ; 44(4) 367-373
Contributi Scientifici - Scientific Papers
 
Validazione dei metodi quantitativi bioanalitici in spettrometria di massa: regole e protocolli sperimentali
Bioanalytical method validation of quantitative mass spectrometry based assay: experimental protocols and regulations
<p>Liquid chromatography-mass spectrometry (LC-MS) technique has rapidly extended the spectrum of clinical chemistry methods during the past decade and it has became a standard tool for endogenous and exogenous substances in research laboratories as well as in many clinical laboratories. To date, many guidelines for bioanalytical method validation have been published, but there is still the need to have specific guidelines and experimental protocols. In particular, we need to further focus and investigate the overall clinical aspects of spectrometry method validation, for both exogenous and endogenous molecules. The aim of the present document is to suggest specific experimental regulations and protocols for bioanalytical LC-MS method validation for exogenous and endogenous molecules, inspired by actual international guidelines and integrated with practical tips to obtain better performance on methods used in routine clinical practice. Here we have introduced new concepts such as &ldquo;normalized matrix effect&rdquo;, and protocols for method validation using &ldquo;pathological samples&rdquo; and &ldquo;altered samples&rdquo;, as these are the most commonly samples encountered in laboratory routine. In conclusion, the new rules and protocols reported in this work do not intend to replace international guidelines; we believe that these rules have to be considered besides the available guidelines with the aim to help the LC-MS users by recommending a number of experimental steps to be performed during each method/kit validation.</p>
Biochimica Clinica ; 42(1) 51-61
Documenti - Documents